Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design
about
Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.A proposal to use iterative, small clinical trials to optimize therapeutic HIV vaccine immunogens to launch therapeutic HIV vaccine development.Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominanceThe HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen TypesIn silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Human Immunodeficiency Virus (HIV).Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point.Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.Characterization of the Protective HIV-1 CTL Epitopes and the Corresponding HLA Class I Alleles: A Step towards Designing CTL Based HIV-1 Vaccine.T cell responses to viral infections - opportunities for Peptide vaccination.Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.Justification for the inclusion of Gag in HIV vaccine candidates.Conserved HIV-1 Gag p24 Epitopes Elicit Cellular Immune Responses That Impact Disease Outcome.The value of HIV protective epitope research for informed vaccine design against diverse viral pathogensHuman Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice.HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Conserved HIV Epitopes for an Effective HIV Vaccine.Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.The Early Antibody-Dependent Cell-Mediated Cytotoxicity Response Is Associated With Lower Viral Set Point in Individuals With Primary HIV Infection
P2860
Q30381239-D61D2C89-1A67-493D-96E2-72B568680C69Q30934059-7F32B546-C06F-4742-BE1A-001E1F23D338Q34869364-19039C8E-F508-4744-8437-8C76BDAD6ED1Q34991038-812056A0-CD95-450E-BB2B-698D3AC4FD3EQ35105393-0DD7400F-8AE2-4ED6-AD17-CAE84E3A272EQ35641132-C7B5662F-7C7F-4AA1-9164-5D669A9A812FQ35797743-EE0810EB-489E-473D-9B82-E1969339798FQ35887235-7069B44D-167A-4AD4-8C94-975B1152EE68Q36487887-17B91446-C81A-4BF2-A3B1-2CC9DB1C2EE3Q37045832-E20AC33B-0751-4DB0-BFE6-A5DDA2EAA182Q37069837-C7215150-640D-47EC-A415-D68E62501C59Q37547306-ECBBCE0B-A62E-4DE6-9C32-69B93951FA4EQ37548329-56C22021-074E-4608-95A8-6CD49281EB9FQ37686906-468123D1-8ABB-49F9-8C6A-59564626F3CEQ37718978-2641458A-9489-4234-AF20-6F60B66710ABQ38184579-E79FD7CD-2B87-4592-B3B2-737DC4A67910Q38662319-66EF51E2-DC83-4C6C-8378-CA9432C68953Q38736699-FDA63CF5-38BE-4EC7-B436-45E65B6989DDQ39169929-24AAF3A1-F13C-4BBB-AD0D-C18E35F42DE9Q40097257-9B9AE56B-376B-48B4-B904-0BE8C2DC4007Q40299563-5A928B0F-4E5F-4C2D-A8C3-EF548E305532Q40348395-C65DEAC7-B2AF-47A7-8ACE-2D6BCC63D460Q40942917-EB3A18B8-CB00-4EC3-AD8D-737A83D32768Q47093684-D415507D-C941-4A16-BA52-95866D9D4470Q47593460-EDEC9B53-55B8-4442-923C-D8F189E183C0Q52580309-8807FF09-2A3F-4ED4-9F69-5170C3C63E1FQ52592228-918E92B1-B5B2-49EA-A208-7D79CFD6A08DQ54984932-512ED9C9-1D6C-4338-AF26-64A87741DEE2Q57816727-D44E3C99-406C-4126-BEA5-6BF59D50C860
P2860
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@ast
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@en
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@nl
type
label
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@ast
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@en
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@nl
prefLabel
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@ast
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@en
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@nl
P2093
P2860
P1433
P1476
Superior control of HIV-1 repl ...... cations for HIV vaccine design
@en
P2093
Ann C Collier
Claire E Stevens
David A Swan
Helen Horton
James I Mullins
Janine Maenza
Natalie Hawkins
Pratima Kunwar
Warren L Dinges
Xuesong Yu
P2860
P304
P356
10.1371/JOURNAL.PONE.0064405
P407
P577
2013-05-31T00:00:00Z